Page 1,232«..1020..1,2311,2321,2331,234..1,2401,250..»

Cannadabis: tissue culture and the future of cannabis cultivation – Health Europa

Posted: December 13, 2019 at 3:50 am

Cannadabis Medical INC they intend to create a healthier and more consciously aware environment for the cannabis industry, and its participants, to thrive in.

Did you know that Cannadabis are Partners with us? Discover their featured Partner Page about a healthier, environmentally conscious cannabis industry.

The company is a family run company that was founded in Humboldt, Saskatchewan.

Founders, Alexander Calkins, BSc and Markus Li, P.Chem, MBA, are personally and emotionally invested in the science of cannabis. They each have family members that are dealing with incurable ailments, complications of which can often become fatal.

In the search for natural products that will improve the quality and longevity of life, the founders began working with cannabis. While there is no likelihood of a cure, the symptom management has been very positive for their family members. After witnessing the improvements, Cannadabis founders Calkins and Li, have dedicated themselves to furthering the medical cannabis movement.

Calkins and Li both have backgrounds in technical science and business. They are experienced cultivators and have a strong understanding of energy systems (practically essential for a power-hungry industry), process automation, and large-scale development.

Their familiarity with multi-industry supply chains has leveraged them into a cannabis development that is simultaneously high-tech, old school, and simple.

Through observation of established global industries, Cannadabis is building a multi-faceted business model based on sustainable practices, a strong genetics portfolio, disruptive technologies, hyper-specialisation, and holistic production.

Driven by a passion to help others in need, Calkins and Li took it upon themselves to bring their methods and expertise to the cannabis world. They recognise and praise the patient independence that medical cannabis can provide.

While they champion the practice of homegrown medicine, they have obligated themselves to providing the safest and highest quality medical products to those who are unable to grow for themselves.

Once Cannadabis has perfected its organic growing system, they will build and operate all future cultivation sites according to (EU) GMP and ISO:9001 2015 standards. By adopting these standards, Cannadabis will have the ability to share their cultivated passion with the world.

To meet the sanitary requirements of GMP and processing limitations of an organic certification, Cannadabis will be using a combination of reactive oxygen, electrolysed water, and radio frequency pasteurisation technologies.

Being a medically focused company, Cannadabis recognises that medical consumers have turned to cannabis because they are looking for natural remedies and are becoming increasingly weary of synthetic medicines.

For Cannadabis, producing medical cannabis using anything other than organic methods would transgress the fundamental sentiment that drives the global, medical movement. That is why Cannadabis is committed to attaining internationally recognised organic certifications on expanded production.

The companys flagship facility is intended to be an R&D focused proving ground for state-of-the-art organic cultivation methods. Cannadabis currently uses an inhouse blended soil, made only with organic ingredients. Their living soil has the benefit of creating terpene dense medicine, reducing cost, and simplifying processes.

With all the nutrients available in the soil, the plants require only water from transplant to harvest. Additionally, the growing medium and all organic waste can be recycled through vermicomposting, further reducing long term costs and needless waste.

Cannadabis will adopt various technologies to reduce energy demand and environmental impact. In addition to using LEDs and solar panels, Cannadabis will use combined heat and power (CHP) (or cooling combined heat power (CCHP)) at their cultivation facilities. CHP units burn natural gas to generate power and the waste heat is used to heat water and the workspace. CHPs are quickly becoming popular for reducing carbon emissions. In certain applications, CHPs reduce carbon emissions by 30-40%, compared to when power is taken from the grid.

Cannadabis will also divert the combustion CO2 into the growing space. CO2 supplementing supercharges growth naturally, increasing yield by 30-60%, and further reducing the carbon emissions from power generation. In the future, expanded cultivations may integrate pyrolysis of waste biomass, which will supply power and nutrient dense biochar to the living soil.

Cannadabis is aspiring to build a unique indoor growing system that uses a combination of solar power, water recycling, CHP (CCHP), pyrolysis, CO2 supplementation and vermicompost to create a no waste, carbon neutral, minimal input, self-regenerating nutrient, off grid, medical grade, organic, indoor cultivation.

Calkins and Li hope to validate the system and then apply the techniques to food cultivation; this type of system could revolutionise the food production in remote locations, like the northern territories, Alaska and would deliver food supply independence to small communities or reservations. Where biomass is abundant, this system would produce all year, requires only labour as inputs, self-generate power off-grid, and would also be carbon negative over extended time frames.

On their path to improving growing efficiency, Cannadabis has developed proprietary tissue culture methods specifically for cannabis. These methods are based upon the decades old horticultural practice that has been essential for the sterile propagation of ornamental and food cultivars; non seed propagation.

Developing an inhouse tissue culture system has the following benefits:1

Tissue culture revitalises cultivars and produces more vigorous plants Regeneration from meristem rids systemic disease; Propagation is significantly more efficient; Starting with 100 traditional cuttings; able to produce 70,000 annual clones; Start with 200 tissue culture vials; produce 2 million annual clones; Uses 1/10 the space of traditional cloning; Per square foot, tissue culturing is >100x more efficient; and Two million annual clones could be produced in less than 3000 square feet.

1000 mother cultivars could be stored inside a refrigerator with no care or maintenance for months, sometimes over a year; and Pest invasion would not affect mother cultures (many cultivators without tissue culture have lost their entire genetic inventory to viruses and fungi).

Cannadabis will be sharing its tissue culture methods with industry members who want to stay one step ahead of pests and systemic disease. Following more development, they will also be making their organic formulations available.

Having collected and grown a large variety of cultivars, both through seed and clone, the Cannadabis founders have noticed a distinct lack of quality in the genetics market. Over time, most of the popular cultivars of the world have been slowly degraded by deleterious breeding practices like selfing (feminising), backcrossing, and poor mother plant maintenance which promotes genetic drift.

The current genetics market is rife with breeders that take prized clones and spray them with colloidal silver to produce feminised seed, or they are crossed onto their own cultivars and backcrossed until stable seed is produced.

While these name sake creations may capture some of the qualities of the original strain, like trichome density or terpene profile, the progeny will lack the genetic diversity needed to produce healthy plants. Often, these weakened strains have reduced yield, potency, and pest resistance. In response to this, Cannadabis has focused on breeding their own high yield, high potency, flavour dense strains for commercial production.

The Cannadabis team is eager to unveil their propriety strains to the domestic and international medical markets. Over the past few years, the founders have started breeding their own cultivars. Currently, the team has focused on a selection of stabilised true breeds (landrace or F5+) for creating original F1 breeds.

Where the F1 generation is created by breeding male and female plants that are distinctly unique from each other; traditional F1s are created by crossing landrace indicas with landrace sativas.

These crosses need to be done with highly stable and uniquely different parents to produce a true F1 progeny that has abundant hybrid vigour. A plant with true hybrid vigour will typically have higher potency, increased pest resistance, and a higher yield than both parent plants; on average yield can be as high as 20% more than either parent.

Due to the nature of the F1 progeny, very few breeders release true F1 seeds. If highly stable progenitors are not used, the seedstock will be incredibly variable, which is unfavourable for consumers, who typically want consistency in their seed. However, as commercial cultivators, Cannadabis believes that F1 hybrids are essential for producing at large scale. The breeding and phenotyping can be a long and arduous process, the fruits of labour are not without commercial benefit.

Building upon the tissue culture and breeding practices, Cannadabis is quickly developing polyploidisation methods for creating ultra-premium cultivars. Polyploidisation is another common horticultural practice that Cannadabis expects to apply to their cannabis breeding projects.

Polyploidisation is a naturally occurring mechanism where the chromosomes of the plant cells become doubled within the same nucleus. This mechanism has played a significant role in speciation of crops, occurring frequently in nature, usually due to stress response.

In the 100 years since scientists discovered polyploidy, there has been rapid development of polyploid breeds. It is estimated that up to 80% of all flowering plants have polyploid varieties.2 Common polyploid cultivars includes wheat, coffee, banana, strawberry, potato, etc.

Polyploidy has been researched since the early 1900s. Scientists first used heat and electrical stress to induce those mechanisms. Today polyploidy is more commonly, and consistently, induced with radiation and stressing chemicals. Interestingly, induced polyploidy is explicitly exempt by most organic certification bodies. These types of breeds typically do not fall under genetically modified until foreign, non-similar species, DNA is introduced to the plant cell.

These polyploids are called autopolyploid (same species), and plants made with dissimilar species are called allopolyploids. Cannadabis will also be exploring organic permitted cell fusion; this would allow breeding with two male plants, or two female plants.

In the past, the following horticulture benefits have been derived from polyploidy and cell fusion, which Cannadabis hopes to similarly apply to the cannabis plant:3

The same can apply to cannabis. Strains can be developed that would never seed regardless of direct pollination; massive utility available to outdoor or indoor cultivators with seeding problems.

Cannadabis hopes to release their first polyploid strains in late 2020.

Cannadabis has begun manufacturing premade tissue culture mediums and are currently distributing them to Western Canadian horticulture stores and Amazon Marketplace; the mediums are a standard blend that works on 95%+ of the founders cultivars. The founders tissue culture experience is being provided to the public in both consumer and commercial grade products.

The introductory products show unfamiliar users how to do tissue culture at home, using proven methods that do not require expensive laboratory equipment. Besides what comes in the starter kit, the everyday home grower will usually have all the remaining materials at home. Commercial format mediums are intended for growers that want the best value and space savings.

Cultivators of any background can find information or help on tissue culture through the Cannadabis homepage. They are posting helpful videos and literature on cannabis tissue culture and hope to share the benefits with every grower. All horticulturalists, cannabis or not, can benefit from having their cloning area be 100x more efficient, through stackable containers. Furthermore, their mother plants can easily be maintained with minimal care. 100-1000 mother cultures can be stored within a refrigerator for 4-8 months, no adding nutrient or water. For larger cultivators, Cannadabis provides PGR matrices to more easily troubleshoot difficult cultivars. They also will custom blend and sterilise mediums to customer preference.

Cannadabis has begun developing an automated cell culture process for mass propagation of cultivars. The economies of scale of which are expected to change the supply chain of the entire cannabis industry. Automated cell culturing will provide starting materials to the industry at a fraction of the cost of inhouse cloning. Clones produced through cell culturing will also have the benefit of being totally sterile and free from disease.

Cannadabis has been offered an NRC-IRAP grant for initial developments of the process and are in early negotiations with a Canadian cannabis company to commercialise. The founders are expecting to file patents, mid 2020, and begin construction of a commercial scale process by mid-2021. Cannadabis anticipates that a 5000 sq ft facility will produce 5+ million clones annually, with minimal labour.

The project is looking to possibly incorporate the production of artificial seeds, which would simplify transportation and ease of storage for cultivators. They will also be developing cryogenic preservation methods. Cultivators around the world are encouraged to reach out to Cannadabis if they are looking to simplify their process, access cell culture benefits, and maximise growing space.

Working with Cannadabis cultured clones will be the most affordable, safe, and efficient way of acquiring starting material. Their services would include meristem culturing to remove systemic disease, and long-term storage of genetic inventory. Partners who end up with a pest could rest easy knowing their mother cultures will be perfectly preserved in tissue culture, and fifty thousand clones for the next crop are still on the way.

Cannadabis Medical and Delta 9 Cannabis have teamed up to provide an affordable, turnkey, tissue culture laboratory, complete with operating procedures, equipment, and cannabis medium recipes.

The two companies have co developed this system for their own commercial use and have recently made the system available for other cultivators. Both companies have recognised that the cannabis industry is still reliant on black market methods of propagation, and as a result, there have been countless incidents of crop and genetic loss in the legal industry; many of the stories circulating are understandably refuted by the companies experiencing such loss.

Rather than ignore the inevitable pest problems, the two companies are going toe to toe with mother nature, developing half century old technology and making it specifically for cannabis. Hopefully delivering the same modicum of control to the rest of the industry; cultivators slow to develop tissue culture science may soon find their genetics and crop totally destroyed by a single, often microscopic pest. On a commercial scale, these pests become essentially impossible to remove without the use of tissue culture.

With feet rooted in genuine care, Cannadabis and Delta 9 are prepared and excited to deliver a tissue culturing system to the global cannabis industry. They recognise the value and utility available to growers, and they also recognise that learning tissue culturing can feel out of reach for cultivators with no prior knowledge, or excess funding to hire an inhouse specialist.

Instead of missing out or paying specialists, cultivators can rely on Cannadabis and Delta 9 to deliver a ready to use laboratory, the development of which was based on maximising value for the growers.

The laboratory comes with only bare essentials and extensive, yet simple, operating procedures. Training materials will detail cannabis specific mediums, sanitation protocols, along with troubleshooting methods for finicky cultivars; an inexperienced grower will be comfortably blending and using mediums on the same day of commissioning. The whole system, equipment and all, will be much more affordable than hiring a tissue culture specialist.

Over the next three years, Cannadabis will be working to establish an expanded cultivation with the hope of supplying medical, organic, indoor grown cannabis to domestic and international markets.

They will also pioneer an original cell culture process that expects to be the most affordable source for starting materials in the world; Cannadabis is especially excited to deliver their polyploid cultivars as starting materials to industry members.

Cannadabis would like to offer an open invitation to all scientists, entrepreneurs, and industry professionals for collaboration. We are actively seeking partners who share a similar vision for the cannabis industry. Any professionals who are driven by a sense of genuine care and have a passion for cannabis medicine are encouraged to reach out.

References

1 hempindustrydaily.com/hemp-cultivators-tissue-culture-increase-propagation-preserve-genetics/2 Meyers, L. A., and Levin, D. A. (2006). On the abundance of polyploids in flowering plants. Evolution 60, 11981206. doi: 10.1111/j.0014 3820.2006.tb01198.x3 http://www.slideshare.net/ranganihennayaka/plant-polyploids4 http://www.frontiersin.org/articles/10.3389/fpls.2019.00476/full5 plantbreeding.coe.uga.edu/index.php?title=5._Polyploidy

Alexander CalkinsCEOCANNADABIS Medical INC+1 306 552 4242alexander@cannadabismedical.caTweet @cannadabiscannadabismedical.ca

This article will appear in the first issue ofMedical Cannabis Networkwhich will be out in January.Clickhereto subscribe.

Read more from the original source:
Cannadabis: tissue culture and the future of cannabis cultivation - Health Europa

Posted in Genetic medicine | Comments Off on Cannadabis: tissue culture and the future of cannabis cultivation – Health Europa

Reviewing Aeterna Zentaris Inc. (AEZS)’s and Magenta Therapeutics Inc. (NASDAQ:MGTA)’s results – The CoinGlobalist

Posted: December 13, 2019 at 3:49 am

Aeterna Zentaris Inc. (NASDAQ:AEZS) and Magenta Therapeutics Inc. (NASDAQ:MGTA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

We can see in table 1 the earnings per share, top-line revenue and valuation of Aeterna Zentaris Inc. and Magenta Therapeutics Inc.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Liquidity

Aeterna Zentaris Inc.s Current Ratio and Quick Ratio are 2.3 and 2.2 respectively. The Current Ratio and Quick Ratio of its competitor Magenta Therapeutics Inc. are 17.2 and 17.2 respectively. Magenta Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Aeterna Zentaris Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Aeterna Zentaris Inc. and Magenta Therapeutics Inc.

On the other hand, Magenta Therapeutics Inc.s potential upside is 30.62% and its consensus target price is $18.

Insider & Institutional Ownership

The shares of both Aeterna Zentaris Inc. and Magenta Therapeutics Inc. are owned by institutional investors at 21.4% and 75.9% respectively. 0.6% are Aeterna Zentaris Inc.s share held by insiders. On the other hand, insiders held about 1.8% of Magenta Therapeutics Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aeterna Zentaris Inc. has -70.92% weaker performance while Magenta Therapeutics Inc. has 133.16% stronger performance.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

More here:
Reviewing Aeterna Zentaris Inc. (AEZS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - The CoinGlobalist

Posted in South Carolina Stem Cells | Comments Off on Reviewing Aeterna Zentaris Inc. (AEZS)’s and Magenta Therapeutics Inc. (NASDAQ:MGTA)’s results – The CoinGlobalist

Deacon Butch King learns to accept the ‘gift’ of cancer – Arkansas Catholic

Posted: December 13, 2019 at 3:48 am

By Aprille HansonAssociate Editor

Aprille Hanson

Deacon Butch King and his wife Debbie (left) stand with their daughter Paula Draeger (center) in front of the Seed of Hope garden at UAMS Winthrop P. Rockefeller Cancer Institute in Little Rock Dec. 4. Last month, King was able to place a seed of hope token into the garden, signifying he is cancer-free, thanks to a stem cell donation from his daughter.

Aprille Hanson

Deacon Butch King and his wife Debbie (left) stand with their daughter Paula Draeger (center) in front of the Seed of Hope garden at UAMS Winthrop P. Rockefeller Cancer Institute in Little Rock Dec. 4. Last month, King was able to place a seed of hope token into the garden, signifying he is cancer-free, thanks to a stem cell donation from his daughter.

Deacon Butch King was given a gift in 2017. He was diagnosed with a rare disease MDS/MPN, myelodysplastic/myeloproliferative neoplasm-unclassifiable to be exact.

The hybrid disease results when bone marrow overproduces unhealthy blood cells, according to University of Arkansas for Medical Sciences in Little Rock.

The diagnosis sent the family on a harrowing journey for the next two and a half years: four changes of insurance coverage and medical facilities, 19 rounds of chemotherapy, 430 lab results, 14 bone marrow biopsies, 11.25 gallons of donated blood and the disease progressing to Acute Myeloid Leukemia.

Looking at a deadly disease as a gift takes a radical faith in God, one that King and his wife Debbie have carried with grace to his cancer-free diagnosis Nov. 4.

It was given to us as a gift. And how do we manage gifts? We care for them, we nurture them, we polish them, show them off with pride and we give thanks to God. Those are his words, our words together. We had a gift and we had to manage it, we didnt get a choice, his wife said.

King was ordained a deacon in 2012, serving at Immaculate Conception Church in North Little Rock. The couple has four children, 12 grandchildren and six great-grandchildren, with another on the way in March. After 23 years of serving in the U.S. Air Force working in secure communications, he spent 22 years with the U.S. Postal Service.

In October 2016, he had a metal stent placed in his heart and could not have any surgeries for the following six months. In November of that year, he twisted his knee at work. When he was finally ready to have knee surgery in May, his lab work was irregular. In June they learned he had developed a rare blood disorder, MDS, which later in the year progressed to MPN. It required a stem cell transplant, with only a 30 percent chance of surviving a transplant.

I was kind of stunned at first, King said. As a deacon, he had been used to visiting the sick in nursing homes and hospitals.

This is one of the stories you can say, I know how you feel because Ive been there or were praying for you and really mean it, he said.

With every roadblock of insurance not covering the procedure or a hospital turning the transplant down because he was high risk, faith prevailed.

In December 2017, their youngest daughter Paula Draeger, 38, was a perfect match for a stem cell transplant, an extremely rare result.

OK, we can do this; were going to heal him. Weve got the perfect match. If this doesnt work, nothing will. So that was just kind of the reaction, lets do it, the married mother of two said.

Debbie King said, Shes a Spina bifida baby. We were told that she would be a vegetable when she had her spinal surgery. So shes a miracle to be here; long before this ever came God had a plan.

Once Medicare kicked in, insurance would cover a transplant if a clinical trial was available. It led the family to 13 visits to University of Oklahoma Stephenson Cancer Center in Oklahoma City, though they refused the transplant.

Debbie King said they specifically chose Oklahoma City because the family had been, and still are, praying daily for Blessed Stanley Rothers intercession.

The martyr, who grew up on a farm in Okarche, Okla., was declared blessed on Sept. 23, 2017, in Oklahoma City. He was killed in 1981 while serving his people in Guatemala.

He needed a miracle. And we said God provides miracles, Debbie King said.

Before we started any treatment we would place the entire illness and what would be happening at Blessed Stanley Rothers gravesite in Oklahoma City, visiting 11 times, she said.

Whats the miracle? The miracle is the faith. And thats what Butch has said, she said.

On March 13, the Kings were told they wouldnt be continuing the trial in Oklahoma.

We were ready to just be on maintenance and enjoy the days we had, she said. On March 14, our 44th wedding anniversary we were celebrating what we thought could be our last one.

But Dr. Appalanaidu Sasapu, hematologist oncologist with the UAMS Stem Cell Transplantation and Cellular Therapy Program, never gave up on them. Because Kings disease had progressed to leukemia in April, the stem cell procedure could now be done at UAMS and covered by insurance.

Draeger said the stem cell donations, done over a weekend via a port, were simple, with no side effects aside from building her energy up in the following week.

For what youre able to give somebody, what you have to endure pales in comparison to what hes been through and what you can give him, she said.

King no longer has the blood disease and is cancer free, though he will continue at least a years worth of chemotherapy treatments.

Since his diagnosis, they attend the smaller St. Patrick Church in North Little Rock for Mass, but he cannot yet return to ministry.

We do our prayer time in the mornings and evenings, we count our blessings every night before we go to bed and we just know, what was our blessing today? Did we see somebody that we havent seen before that God put in our path? Is it a new doctor who is going to take this on? King said.

But through this whole process weve been truly blessed, had no regrets. If I had to do it over, if thats the path of my life that God wants me to take, then Ill do it.

Please read our Comments Policy before posting.

See the article here:
Deacon Butch King learns to accept the 'gift' of cancer - Arkansas Catholic

Posted in Arkansas Stem Cells | Comments Off on Deacon Butch King learns to accept the ‘gift’ of cancer – Arkansas Catholic

The 2019 Outsiders of the Year – Outside

Posted: December 13, 2019 at 3:47 am

Our annual Outsiders of the Year list honors the most influential people changing our outdoor world. For 2019, our staff and contributorsnominated an original list of 81 candidates, then got busy whittling them down to a select few. The U.S. womens national soccer team handily won the top spot, not only bringing home their second consecutive World Cup victory, but fighting a battle for gender equality at the same time. Others making the final cut include the teenage leader of a global climate movement; a mountain biker whosbreaking Americas long dry spell on the World Cup circuit; a Nepali climber whos shattering a mountaineering speed record, and many more. Here are the athletes, entrepreneurs, activists, and creatives who blew up the status quo in 2019.

(Photo: Michael Regan/FIFA/Getty)

They move across the field as one, shifting with the ball, actions precisely calibrated. A beautiful, brutally efficient machine. And an unbeatable one.

The U.S. Womens National Team stormed through the World Cup this summer, never once trailing in a game, ending the monthlong contest with a championship trophy. They became back-to-back World Cup winners. Their opener, a 130 rout of Thailand, was the most lopsided victory in World Cup history. At a time when womens soccer has never been more competitive, they scored 26 goals over the course of the tournament, double the amount of the next-highest-scoring team. And they did it while waging an off-the-field battle against gender discrimination.

In part, they were able to pull this off because they have some of the best players in the world. Alex Morgan, who tallied five goals in the opener and ruffled feathers when she mimed sipping tea after scoring on the English. Rose Lavelle, whose tricky movement spun defenders in circles. Crystal Dunn, who showed unmatched versatility and made defense look exciting by shutting down opponents as left back. (Shes normally a striker or attacking midfielder.) Pink-haired co-captain Megan Rapinoe, who netted ice-in-the-veins penalty kicks. Tobin Heaths magical footwork, Julie Ertzs power, Lindsey Horans command of the midfield, Christen Presss preternatural scoring ability. Et cetera. Regarding the depth of the squads bench, defender Ali Krieger quipped to The New York Times, We have the best team in the world and the second-best team in the world. That swagger was matched with exuberant post-goal celebrations (see: Rapinoe, arms spread wide, chin held high) that garnered the team the full range of media descriptions: awesomely formidable, supremely confident, arrogant, ruthless, disgraceful, even villains.

Call them whatever you want, but they have inspired a massive American fan base to give a crap about womens soccer. Thousands traveled to see them play in France, while millions smashed audience records on TV. A stop on their victory tour in Philadelphia drew the largest audience in U.S. history for an exhibition soccer match: nearly 50,000 attended on a Thursday night in late August to see the U.S. beat Portugal 40 in an essentially meaningless game. (Even after the World Cup, the National Womens Soccer League, in which every member of the national team plays, saw sold-out matches for a majority of clubs.) And they did all this with less marketing, lower pay, and fewer resources than their male counterparts, who didnt even qualify for the previous mens World Cup, in 2018.

But the women of the national team knew what they deserved long before they won the World Cup (again). Which is why, in March, instead of focusing exclusively on their preparation for the biggest soccer tournament in the world, 28 members of the team22 of whom were selected for the 23-woman World Cup rostersued the U.S. Soccer Federation for gender discrimination. They wanted equal pay, yes, but they also wanted better workplace conditions. Whether its youth team programs, marketing, the branding of the team, how they sell tickets, what they spend advertising money on, what they pay each side, what they spend on support staff, what they spend on coaching, whats the travel budgetits all of that, Rapinoe told The New York Times Magazine in July. The compensation is sort of the last big part. Besides suing their own federation, the players have also criticized FIFA, the sports international governing body, for lackluster support of female players.

Were trying to make it better for the generations after us, Lavelle told Outside in September, noting that their fight is part of a larger global effort. There are a lot of people in womens soccer pushing for change. Its not just our team. Its a really cool time. Its very unifying for the sport. Over the past few years, the national teams from Spain, Australia, Argentina, Nigeria, Sweden, Afghanistan, Puerto Rico, Jamaica, Chile, and elsewhere have protested for better conditions or pay. (There have been similar movements in cycling, surfing, hockey, basketball, and other sports.)

The women of the national team fight for other social issues, too, even at a time when some fans say that sports should be an apolitical arena. Rapinoe continues to support former NFL quarterback Colin Kaepernicks protest against racial injustice by keeping her hands behind her back and declining to sing during the national anthem. And she, along with other team members and head coach Jill Ellis, often speaks out for LGBTQ representation and rights. In France, after she scored two goals in the teams quarterfinal victory over the home country, Rapinoe told a group of journalists, Go gays! adding, To be gay and fabulous during pride month at the World Cup is nice.

Rapinoe also found herself at the center of a national controversy mid-tournament when the magazine Eight by Eight released a video of her saying, Im not going to the fucking White House if the team won. (The video was shot earlier in the year.) After the clip went viral, President Trump tweeted in response, Megan should WIN first before she TALKS! Finish the job!

And so she did. To be able to couple that with everything off the field, Rapinoe said after the final, to back up all of those words with performances and to back up all of those performances with words, its just incredible.

Ultimately, the women of the national team probably hope that one day they no longer have to be activists. They want womens sports to be mainstream. They want equal pay and resources, and for LGBTQ acceptance to be the norm. They want to be able to focus on being soccer players.

But for now, theyll do it all. And you can count on them to finish the job. Jessica Luther

(Photo: McNair Evans/Redux)

For all the recycling and LED-bulb burning we do, few personal choices benefit the earth more than giving up meat. Curb our cravings for post-ride burgers and well slash deforestation and greenhouse gases. The problem? Meat is delicious, says biochemist and former Stanford University professor Pat Brown. Figure out why in molecular terms and you will have gone a long way toward solving the biggest threat our species has ever faced.

Which is why Brown, 65, founded California-based Impossible Foods in 2011: to convert meat lovers to a plant-based imitation. But it wasnt until 2019 that his plan began to lookand tastemore like reality. In January, the company released the Impossible Burger 2.0, a grill-sizzling, aroma-exploding ground-beef imposter that even chefs like Momofukus David Chang cant believe didnt once chew its cud. Bill Gates, Serena Williams, and Jay-Z joined investors in a $300 million round of fundraising this year. Burger King is on board, too, with the Impossible Whopper.

The secret to the faux burgers meaty flavor: leghemoglobin, or heme, an iron-containing protein that Browns scientists synthesized by fermenting genetically engineered yeast. With ersatz chicken, fish, and pork products on the way, Brown hopes that by 2035 hell have helped remove animals from the food chain. How? Bycoming up with a technology that does a better job of delivering what consumers want, he says. The market will take care of the rest. Tim Neville

(Photo: Patrick Smith/Getty)

For most of her career, Caster Semenya, 28, has had to convince people that she has the right to compete with other female athletes.

In 2009, following her 800-meter world-championship win, the International Association of Athletics Federations, the governing body for track and field, subjected Semenya to a sex-verification test. The IAAF never released the results, but it cleared Semenya to return to competition in 2010. In the following years, she won two Olympic gold medals in the 800, and was undefeated at that distance from 2016 onward.

In 2018, the IAAF created a new policy that would affect athletes with differences of sexual development and naturally occurring but unusually high levels of testosterone for women. The rule applied to Semenya. Based on the notion that high testosterone levels in women give them an unfair advantage, the IAAF mandated that athletes competing in events including the womens 400, 800, and 1,500 meters must sustain a level at or below five nanomoles per liter for at least six months, even if it means taking hormones to do so. Semenya fought the decision. I am a woman and I am a world-class athlete. The IAAF will not drug me or stop me from being who I am, she said in a statement in May. Many in the medical community backed her, saying that the IAAFs decision was based on flawed research. Some reasoned that testosterone levels have little effect on athletic performance, or no more than other naturally occurring biological advantages such as height, body composition, and response to training.

But in July, the Swiss Supreme Court (the Court of Arbitration for Sport is based in Lausanne) upheld the IAAFs decision, barring Semenya from competing in the world championships and, effectively, any shorter-distance races. As other governing bodies and sporting institutions create and clarify their policies, the court decision was seen by some as a blow to any athlete who doesnt fit into traditionally defined categories of sex.

For her part, Semenya made it clear shed rather stand for what she believes ineven if it means sacrificing her career at its pinnacle. In September, she announced a professional soccer contract with a South African club, calling it a new journey. Gordy Megroz

(Photo: Courtesy Peak Design; Philip Montgomery)

In 2017, Peak Design founder and CEO Peter Dering surveyed the mounds of fossil-fuel-based fabrics used to make his companys camera bags and realized how bad it was for the planet. Then he discovered something shocking: for a mere $60,000 of its $30 million in sales that year, the company could buy enough credits to negate every last bit of its carbon emissions from its supply chain, from raw-materials extraction to shipping. And for $200,000, he could retroactively offset the companys entire existence since it began in 2011.

I thought, this is either B.S., or every company on the planet should be doing it, says Dering, 36. And it isnt B.S.

Responsible companies have long sought to mitigate their carbon footprints by calculating emissions and then purchasing credits that help fund projects that reduce an equivalent amount of carbon. But the standard calculation mostly considers corporate travel and energy consumption, which is often just a fraction of the true amount. Dering teamed up with Jonathan Cedar, CEO of BioLite (maker of fuel-efficient cookstoves and portable lights), to push companies of all kinds to tackle the entirety of their global-warming filth. In February, they launched Climate Neutral, a nonprofit that helps brands calculate their cradle to consumer footprint, reduce it, and figure out how to offset the rest in a low-cost way. Weve created tools that make this as easy as using QuickBooks, says Cedar, 39.

Eighteen companies signed up in August, including Allbirds, Avocado Mattress, and Kleen Kanteen, and that number is likely to triple by the end of the year. By the end of 2021, Climate Neutral hopes to have 700 brands contributing more than $260 billion to offset 131 million tons of carbona full 2 percent of U.S. emissions. Consumers can look for Climate Neutral certification on member companies goods and services to support companies that are taking emissions reduction seriously.

Dering and Cedar still want more: a policy shift. How big of a collection of brands do we need for governments to say this is what responsible business looks like and it doesnt ruin the economy? Cedar says. Thats the tipping point. T.N.

(Photo: Schneiter Family Archives)

In June, Schneiter, a ten-year-old from Glenwood Springs, Colorado, climbed the Nose, the iconic 31-pitch route up El Capitan in Yosemite. She completed it in five daysmost do it in three or fourwith her dad, Mike Schneiter, and a family friend. She shared her account of the trip with Outside.

My dad wanted to do a shorter route. But I wanted to do the Nose. Its a classic. It stands out. To prepare, I had to learn some new skills. We did a practice night on a portaledge in Colorado. People ask, What if you fall off in the middle of the night? I say, Well, youre still tied in.

That morning I ate vanilla-blueberry granola with whipping cream. As we were hiking to the base of El Cap, I was scared I might not get to the top. But mainly I was excited.

Ive been climbing since I was a toddler. Climbing has always been something we do as a family. I thought I might be one of the youngest girls to climb El Cap, but thats not why I was doing it. I was doing El Cap because I climb and it was one of my goals.

I never wanted to quit, but I definitely had some moments where I was like, Dad, I know its only noon, but can we stop for the day? I would whistle when I was nervous. I kept thinking, When Im done, we get to eat pizza.

I was happy, but sad it was over. My dad made a point: I can climb El Cap again, but I can only do it for the first time once.

Im in fifth grade. When people at school ask what I did over the summer, I dont like to brag, but I also dont want to not share, because climbing the Nose is cool. Im trying to inspire other girls to climb and be active. As told to Megan Michelson

(Photo: Yvette Roman Photography)

The Chesters had no clue what they were getting into when they bought 214 acres of dried-up farmland north of Los Angeles in 2011. At the time, John was a burnt-out Hollywood filmmaker and Molly was a private chef. After Molly couldnt find the type of nutrient-rich produce she was looking forand they were kicked out of their Santa Monica apartment because of their barking dogthey decided to try farming. It was pretty much as naive as that, John says. What we hadnt anticipated is that turning the engine of an ecosystem back on is like opening Pandoras box. Youre inviting nature back in. The Chesters focused on an old-fashioned regenerative style of farming, introducing a wide variety of crops and animals to reinvigorate the soil.

John sold all but one camera when he left the film industry. He used it to capture close-up shots of the farm coming to life. I felt like I was seeing things that had never been photographed, he says. Five years in, he decided to hire a crew and make a feature film starring himself and Molly, a pregnant pig named Emma, and a chicken-killing coyote as a villain.

The eight-year transformation of Apricot Lane Farms is captured in the visually stunning, at times surprisingly intense documentary The Biggest Little Farm. The sleeper hit was a Sundance favorite, won best of festival at the Boulder International Film Festival, and hit theaters nationwide in May 2019. It took in more than $4 million at the box office, but more important, it reminded us that the food on our plate comes from somewhere, and the dirt it stems from has a story of its own. M.M.

(Photo: Dustin Satloff/Getty)

Kate Courtney can barely keep up with her Instagram. She has more than 300,000 followers (@kateplusfate), and the din of notifications can feel overwhelming. But she keeps an eagle eye out for one type of post. I try really hard to message back all the NICA kids, she says, referring to the National Interscholastic Cycling Association, which organizes middle and high school mountain-bike races across the country (Courtney is a proud NICA alum).

Its not enough just to be fast anymore. Pro athletes are expected to be Very Online. Some polish their profiles to a high shine; Courtney rides her own line. There are the obligatory golden-hour shots, but her Insta also has quirky strength-training videos and footage of total yard saleslike her endoing on a training ride this spring. Pop over to YouTube and you can see her rap 50 Cents P.I.M.P. Even on her blog, she keeps her eyes off her navel and on the true prize: finding great tacos.

The 24-year-old is impossible not to like. It helps that shes one of the fastest mountain-bike racers in the world. Last fall, during her debut year in the elite field, Courtney became the first American in 17 years to win the UCI cross-country world championship. A year later, in September, she won the overall world title, accumulating the most points in a season that also included three race wins.

Her personal magnetism and success are reviving interest in American cross-country racing and drawing new fans to the sport. And theyre getting one hell of a show. Her two titles set a high bar for other U.S. pros, and theyre rising to it. Thank you for showing us whats possible, fellow American racer Chloe Woodruff wrote to Courtney on Instagram. At press time, the U.S. womens team was ranked second in the world and poised for a shot at the maximum allotment of three 2020 Olympic slots.

Courtney has already clinched one of those tickets to Tokyo. Before then, theres plenty for fans to look forward to: she plans to document her entire journey to the starting linebruises, tacos, face plants, and all. AC Shilton

(Photo: Maddie Meyer/Getty)

You might not know his name yet, but 23-year-old Caeleb Dressel is taking swimming by stormand breaking Michael Phelpss records. In July, Dressel won eight medals at the World Championships (six of them gold) in Gwangju, South Korea, eclipsing the seven-medal record set by Phelps at the Shanghai worlds in 2011. Heres what it took to make history. G.M.

49.5: Dressels time in the 100-meter butterfly semifinal, which outdid Phelpss ten-year-old world record by 0.32 seconds.

0: Individual gold medals won by other American men at this years World Championships.

21: Heats Dressel swam on his way to eight medals.

6: Number of drug tests Dresselestimates he underwent at theWorld Championships.

5: Records set by Dressel in South Korea, the most held by any swimmer at a World Championship meet. (The previous was four records at a single worlds meet.)

9: Wins Dressel will need at the 2020 Games in Tokyo to break Phelpss records of gold medals won and total medals won in a single Olympics.

50/25/25: The percentage of Dressels meal plate that he targets for carbs, protein, and veggies and fruits, respectively. I dont count calories, I eat until Im full. That is my bodys way of telling me how much fuel I need, he says.

3: Times Dressel has read the book Zen in the Martial Arts, by Joe Hyams. I read it in high school before the junior worlds and in 2017 before the World Championships [in Budapest, where he won seven golden medals]. I read it again before the World Championships in 2019. So I need to start keeping that a tradition, he told NBC Sports in August.

3: Animals Dressel has tattooed on his bodya bear (his favorite animal), an eagle, and a gator (hes from Florida).

(Photo: Matty Wong)

A few summers ago, Tracy Nguyen-Chung walked into a fly shop to buy some strike indicators and walked out with an idea that could change an industry. Since the age of six, Nguyen-Chung had been prowling rivers for trout and, as she got older, salmon. But as a short, queer Asian woman, the filmmaker and publicist from L.A. wasnt terribly surprised that day when a sales clerk offered herbut not her male frienda free 101 class. She declined, but the clerk doubled down: Its always good to brush up.

It was that sort of presumptuous encounter that led Nguyen-Chung, now 34, to send up a bat signal to find other fish-crazed or even just curious minorities who might feel uncomfortable wading into a space long ruled by tweedy white guys. I wondered how many more people like me might be out there, she says.

A lot, it turned out. Since Nguyen-Chung founded Brown Folks Fishing in February 2018, the group has swelled to over 4,000 online followers (@brownfolksfishing) and deployed 18 ambassadors. It connects people of color through free events, many of which offer opportunities to fish (and all of which include food). Together with fly-fishing brand Orvis and other industry leaders, Nguyen-Chung is also creating a pledge program, complete with education materials, for fly shops and guides that want to be more inclusive.

As the daughter of Vietnam War refugees, Nguyen-Chung sees fishing as a way for her to relate with the stories of her father, who used to help his family make and sell fish sauce out of their catch from the rivers and sea around central Vietnam. Through that lens, she says, preserving the environment and fishing take on added meaning for people of color. It comes down to our survival in a very different way. T.N.

(Photo: Erich Spiess/Red Bull Content Pool)

Lindsey Vonn never wanted to be the best female skier of all time, a title she locked up with her 82 career World Cup wins. She wanted to be the best period. And while she retired in February four victories short of all-time record holder Ingemar Stenmarks 86, the 35-year-old boasts wins in five downhill disciplinesa feat of versatility Stenmark never achieved. Throw in the grit shes displayed through one post-crash comeback after another (and the fact that heir apparent Mikaela Shiffrin is still 20victories shy of Vonns mark) and were ready to say the worlds greatest skier just left the building. Fight us. Gloria Liu

(Photo: Atta/Lukasz Warzecha)

Last year, worldwide tourist arrivals reached 1.4 billion two years earlier than predicted. Meanwhile, overtourism wreaks havoc on popular destinations and carbon emissions from air travel grows faster than expected. That puts Shannon Stowell, 51, CEO of the Adventure Travel Trade Association, in a tough spot: How does he steer his niche of the industry toward sustainability without becoming a pariah? Stowell has put an increasing amount of what he calls positive peer pressure on his membership basenearly 1,400 businesses, including tour operators and hotelsto minimize their impact on vulnerable places, wildlife, and people. Speaking at an annual ATTA summit in Italy last year, Stowell broached the topic of overtourism, saying, Were consuming ourselves to seeming inevitable destruction. But he still believes change is possible. We asked him how. Stephanie Pearson

OUTSIDE: How should we defineadventure travel today?STOWELL: The intersection of nature, culture, and physical activity. Mainstream travelers think bungee jumping and ice climbing, but they dont take into consideration nonexploitative cultural interaction with local people, which is a huge element of adventure travel.

What are some examples of what the ATTA does?We just completed a program with the country of Jordan so they can train, certify, and regulate adventure guides. Were also giving technical advice to Airbnb on safety and sustainability. And we launched the Adventure Travel Conservation Fund, which supports projects that protect natural and cultural resources.

Whats your solution toovertourism?The industry should stop using arrivals as a measure of success. Instead we should ask: How are the locals doing? How is the social fabric? How is the wildlife doing? Places that are good to live in are good to visit. I wouldnt mind seeing arrivals decline until we get it right. Also, traffic management. Peru is making a brilliant move to promote venues other than Machu Picchu. Adventure travel is an opportunity for destinations to start sending people off the beaten path.

How can travelers see the world more responsibly?Longer trips fewer times per year is one solution. It helps people decompress on their vacations, interact more with locals, fly less. And people should buy carbon offsets. When my wife and I drove from Washington to Colorado, we went online and researched how much to buy. I double-offset. Instead of just getting your carbon to zero, do quadruple if you can afford it.

(Photo: Michael Campanella/eyevine/Redux)

In August 2018, then 15-year-old Greta Thunberg began skipping school to protest outside Swedish parliament, demanding that her country reduce carbon emissions in accordance with the 2016 Paris Agreement. She kept at it every Friday for months thereafter, through rain, sleet, snow, and ice, attracting the interest of media and her peers. By March, two million students and adults in 135 countries were taking part in weekly strikes, dubbed #FridaysForFuture, earning Thunberg a nomination for the Nobel Peace Prize. By August, that number had escalated to 3.6 million protestors in 169 countries. In September, Thunberg arrived by sailboat at the UN Climate Action Summit in New York City, where she made a stirring speech to world leaders (well be watching you) that made headlines.

Shes been able to speak with the appropriate bluntness and still have people listen, perhaps because of her age and perhaps because her bold action gives her a real moral authority, says Bill McKibben, author of The End of Nature and leader of environmental-advocacy group 350.org. There are thousands of other Gretas out there now, young people who are engaged, doing great work.

Thunberg attributes her single-minded devotion to her cause to her Aspergers syndrome. I see the world in a different way, with a different perspective, she told a Norwegian talk-show host in January. I see things very much as black and white. Most people say nothing is black and white. But the climate question actually is. We have to stop emissions. S.P.

(Photo: Nirmal Purja Project Possible LTD 2019)

On October 29, Nirmal Nims Purja stood onthe summit of Tibets Shishapangma andmade history. It wasthe 14th and final of the worlds 8,000-meter peaks hedclimbed in a littleover six months, smashing the previous record of just under eight years.

Purja isnt the typical alpine record setter. He grew up in the lush lowlands of Nepal, not America or Europe, where most famous, well-funded mountaineers hail from. He only started climbing in 2012. His career instead has been in the military, first in the UKs elite, Nepali-only Gurkha regiment, then as a special-forces officer in the British Army. He left his position in 2018 to pursue what he calls Project Possible, scraping together his budget through GoFundMe and small sponsorships.

Though his use of bottled oxygen and a climbing team rankledsome purists, Purja brushedoff criticism, pointing out that his style allowed him to help stranded climbers. During Project Possible, he wassupported by high-profile alpinists likeConrad Anker and Jimmy Chin, and by fans from the Indian subcontinent who wanted to see the record shattered by a local. Project Possible is for Nepalese climbers, he says, who have always been at the front of the 8,000ers but have never gotten the credit. Philip Kiefer

April 23: Nims summits Annapurna. One day later, he spearheads the rescue of a climber stranded on the mountain, providing him with oxygen. (The man later died in a hospital.)May 12: Nims and his team ascend Dhaulagiri and immediately downclimb through the night to reach base camp, where a helicopter awaits to take them to Kanchenjunga, the next mountain.May 15: On the way down from Kanchenjunga, Nims and his team come across a climber and a guide who are out of oxygen. Despite having barely slept in five days, the group help the pair down. They subsequently encounter a third stricken climber who was abandoned by his guide. They give the rescued men their oxygen, but two of the three climbers die on the way down when it runs out.May 2224: On his way up Mount Everest, Nims snaps a now iconic photo of dozens of climbers logjammed below the summit, which goes viral. Just ten hours later, he ascends Lhotse. Two days later, he stands atop nearby Makalu, setting a world record for fastest ascent of the trio.

July 3: Nims summits Nanga Parbat.July 1518: The team climbs Gasherbrum 1 and Gasherbrum 2.July 2124: Nims arrives at the base of K2. Weather has forced other climbers to turn back, but his team opens a route and makes the summit three days later.July 26: Two days after summiting K2, the team climbs Broad Peaktheir eleventh 8,000er in just over three months.

September 2327: Nims summits Cho Oyu, then Manaslu. Afterward, becauseShishapangma is closed for the season, he appeals the Chinese government for access, even rallyinghis Instagram followers to send e-mails, too: I think if we all go as a collective force, it may help.October 29: After receiving a special permit from China, Nims stands on top of Shishapangma, completing his Project Possible in six months and seven days.

Go here to see the original:
The 2019 Outsiders of the Year - Outside

Posted in Testosterone Shots | Comments Off on The 2019 Outsiders of the Year – Outside

Fishy genetics: A behind-the-scenes look at UCD’s Area 52 – Siliconrepublic.com

Posted: December 12, 2019 at 12:45 pm

Jens Carlsson of the UCD School of Biology is co-founder of the Area 52 research group that aims to solve a variety of genetic questions.

After completing his PhD in 2001, followed by a stint at the Danish Institute for Freshwater Research in Silkeborg, assistant professor Jens Carlsson travelled to the US in 2002 to work as a postdoc at the Virginia Institute for Marine Science.

In 2007, he was appointed a visiting associate professor at Duke University, North Carolina, to research the population structure of striped sea bass.

In 2009, he travelled to Ireland to work at University College Cork as a senior research fellow, which included work on deep sea vessels. Then, in 2012, he made the move to University College Dublin and established his research group, Area 52.

Too many people have been watching the CSI TV series and have strange ideas of how a modern genetics laboratory works JENS CARLSSON

I think I have had an interest in fish since I was introduced to fishing as a kid. While completing my BSc project, I was fascinated by the questions you could ask and answer using scientific approaches.

The freedom that academic research has for coming up with projects and then sourcing funding, to actually examine these questions, was probably the reason why I stayed on in science.

The research group Area 52 quickly developed when I started working in UCD. It is now a rather diverse group and we take on research questions from a wide range of disciplines from viral diseases in fish to identification of human remains.

It is the use of genetic methods that allows us to work with these very diverse questions and, so far, all organisms have DNA or RNA so there are a huge variety of questions that we can address.

This also means that we collaborate with a large number of colleagues. While we have the genetic expertise, we also need to work with people who understand the biology and ecology of the organisms.

When Area 52 started, it was only myself and my wife and lab manager in the lab group. But now it has grown significantly and consists of undergraduates, summer interns, visiting students, MSc students, PhD candidates, postdocs, research fellows and research scientists.

I believe that genetics has the capacity to answer questions that no other research field can do.

For example, when you look at marine fish, there are no clear barriers preventing different populations from mixing. However, this does not mean that the fish all belong to the same biological unit or population.

While fish from multiple biological units can mix at feeding areas, they often return to specific spawning sites with each spawning site representing a single biological unit.

Multiple species have been shown using genetics separated into different populations to represent different biological units. This has profound implications for the management of fisheries species, as the level where management needs to take place is natural biological units and this might differ depending on the time of the year.

You might have multiple populations mixing at feeding grounds and it is very difficult to say which fish came from which population when being caught in commercial fisheries as they tend to look the same. However, by using genetic tools we are able to say which individual belongs to which population.

Furthermore, Area 52 has a strong focus on developing non-invasive sampling methods for studies of terrestrial mammals such as elephants, zebras and giraffes primarily in Kenya.

It is often very difficult and invasive to collect genetic material for these animals. We focus on using scat samples that are completely non-invasive. The animal does its business and we collect the scat and use that as source of genetic material.

Area 52 often works with method development and these methods can obviously be used in the commercial world. For example, the management of fisheries species and the integrity of supply chains.

However, the main focus of the lab is in deploying the methods we develop in conservation and environmental monitoring of water ecosystems.

It is always difficult to find time to do the research. You are teaching, mentoring, doing research and administration. At the same time, you need to secure funding for your research and that is difficult.

This is not only because of the lack of time, but also because of the strong competition among researchers for the very limited funding. This means that you can spend significant time on writing a grant application and then it is not funded. I wish the success rate of grants would be higher.

Too many people have been watching the CSI TV series and have strange ideas of how a modern genetics laboratory works.

The big question is climate change and how that will affect distribution and survival of species. This is a very important question requiring collaboration among a large number of researchers from many different fields of science.

Are you a researcher with an interesting project to share? Let us know by emailing editorial@siliconrepublic.com with the subject line Science Uncovered.

Original post:
Fishy genetics: A behind-the-scenes look at UCD's Area 52 - Siliconrepublic.com

Posted in Genetics | Comments Off on Fishy genetics: A behind-the-scenes look at UCD’s Area 52 – Siliconrepublic.com

A New Genetic Based Dating App Will Soon Arrive in The Market – Science Market News

Posted: December 12, 2019 at 12:45 pm

Harvard biologist George Church already needed to apologize for a palling around with Jeffrey Epstein even after the financier pleaded to responsible for preying on minors a decade in the past. Now hes elevating eyebrows once morewith plans for a genetics-based courting app.

In an interview with 60 Minutes, Church stated his expertise would pair people based on the propensity of their genes, when mixed in kids, to remove hereditary ailments. Yuko, in contrast, the app, as described, to the Nazi purpose of cultivating a grasp race: I believed we realized after World War II that we werent going to be doing that, she stated.

The church was a part of the coterie of scientists with whom Epstein ingratiated himself via large donations, and Epstein helped bankroll his lab from 2005 to 2007. Church has admitted he repeatedly met and spoke with Epstein for years after the 2008 plea deal that landed him on the intercourse-offender registry.

Epstein had a twisted take on genetics, internet hosting scientific conferences at which he expressed his want to propagate his personal genome by impregnating as much as 20 girls at a time at his New Mexico ranch, like cattle inventory.

Within the 60 Minutes interview, Church referred to as his ties to Epstein unlucky and added: You do not all the time know your donors in addition to you want to.

However, a lot of the phase was dedicated to Churchs genetic-engineering work at Harvard Medical School, together with the app that might theoretically display out potential mates with the improper DNA.

The geneticist didnt drop the apps to identify, or how far alongside its in improvement. He additionally didnt reply to a request for a remark.

Within the interview, the Church acknowledged the drawbacks of genetic sorting. He suffers from dyslexia, consideration deficit dysfunction, and narcolepsyissues that may render him an incompatible match to many. Yuko stated the choice standards could be a sticking level for Churchs app thought.

More here:
A New Genetic Based Dating App Will Soon Arrive in The Market - Science Market News

Posted in Genetics | Comments Off on A New Genetic Based Dating App Will Soon Arrive in The Market – Science Market News

Does the ‘genetics revolution’ unsettle you? Here is a guide, and reasons to be hopeful – Genetic Literacy Project

Posted: December 12, 2019 at 12:45 pm

Its that time of year again an avalanche of ads urging us to drool into tubes so companies can spit back verdicts on our pasts, presents, and futures. Judging from my emails, those unceasing ads have inspired many questions about genetics in general.

Among the emails that pinged in recently:

So I started a list of my e-mails, with apologies to Hillary, and extracted three recurring themes: transgender identity, when a human life begins, and by far the largest group: interpreting DNA test results, either consumer or clinical.

What do you think about a new studythat found 20 genetic markers of transgender identity? asked a reporter from The Times of London In March 2018. Id suggested just such a study a year earlier, which hed found here.

Impressed with the study, I agreed to comment. But the reporter forgot to distinguish me from the researcher, and so throughout Europe, I was suddenly an expert on transgender genes. And that inspired some telling emails.

The first, from a trans woman born in 1948, shared her 70-page story:

As far back as I can remember I thought nothing of going into my mothers closet, pulling down her nightgowns, and putting them on. They were soft, they smelled of her, and they felt so perfect. This was me. Everything feminine fascinated me. Anything male repelled me. I wanted to emerge myself in the female world. But no matter what I did, I just couldnt look like Mommy.

Another transgender woman wrote:

I would love to have that degree of certainty that a genetic study would show. Parents would be able to perhaps work with their children instead of ignoring it either intentionally or out of ignorance.

A recent email from 58-year-old Edith brought up nature v nurture:

Two of my nine nieces and nephews are transitioning. My family has an overall fluid concept of gender identity, which we discussed with each other before either child made it known they were trans. I find myself wondering if this is true in other families.

Me too.

I repost 17 timepoints whenever womens reproductive rights are threatened, or I read or hear a comment that indicates ignorance of biology. The idea of the list came to me when considering that an embryos genome turns on at day 5, but it cant possibly exist at that point outside of a womans body.

One woman asked about fetal rights. Her ex had given her an herbal abortion tea without her knowledge when she was pregnant. Her baby so far is healthy, but she wants a court to recognize the tea-poisoning as child abuse. At what point in utero does a fetus have rights? It seems to vary state to state, she wrote.

Celia Collias, a statistics major at the University of North Carolina, offered a compelling perspective: distinguishing two types of viability. Natural ability to be physiologically independent for a human fetus is around 24 weeks. Technologically assisted viability for a human fetus is 21 weeks.

If we dont use natural viability as the cut off for reproductive rights, Ms. Collias argues, then those rights will erode as technology sets back the age of assisted viability:

Technologically assisted viability is not free. If we allow that to be the benchmark, its going to cost society a lot to care for all those fetuses where would that money come from?

Good question.

Is he really my brother? asked the woman who sent me scanned columns of genetic markers. I circled 16 of 38 that they share and sent it back: Yes.

I dont have mutations in BRCA1 or 2, so Im ok, right? I do have a mutation in ATM (or p53 or CHEK2 or PTEN or RAD51 or a few dozenothers). Inherited mutations for cancer risk go beyond the most common ones in the BRCA pair, and altogether they account for only 5 percent of cases. Yes, shes at high risk.

BRCA brings up the limited variant problem. Consumer DNA tests, for cancer or single-gene diseases, are likely to check for only the most common variants, such as a handful of mutations in the CFTR gene behind cystic fibrosis, which has more than 1,700. These health reports may provide a false sense of reassurance and should not be used for making any health decisions without confirmation testing, said Edward Esplin, MD, of Invitae, a clinical testing company, at the American Society of Human Genetics conference in October, catalyzing a flood of headlines.

I had a prenatal screen for 125 genes and one is a variant of uncertain significance. What the heck is a VUS? Do I have a mutation or not?

A VUS is a gene variant that isnt common, but hasnt shown up in someone with a disease and reported in the medical literature. Yet. I explain here.

My ethnicity estimate changed overnight. Huh? When an ancestry company adds a new group to its database of reference populations, the sections of those pie charts can shift, or a new one appear.

Im 20 weeks pregnant. The fetus has a microduplication of chromosome 18. Is that a problem? The healthy dad-to-be also had the tiny extra bit of DNA. So, no.

I just found out that I have an extra Y chromosome. Ive had severe acne since my early teens, and today Im 62 and weigh 295 pounds. Im a biker, football player, and served time for selling pot. Did my extra chromosome get me arrested?

Probably not. Being in the wrong place at the wrong time, before decriminalization, was more likely at fault.

Because most of my email brings up medical matters, heres a short guide to getting help in making sense of DNA test results related to health. (For interpreting ancestry findings, the International Society of Genetic Genealogy is an excellent resource.)

Its important to distinguish consumer DNA tests, which anyone can take by purchasing a kit and spitting or swizzling a cheekbrush, from clinical DNA tests, which a health care provider orders and the FDAs Clinical Laboratory Improvement Amendments (CLIA) regulate.

Like mushrooms materializing after a warm rain, articles, websites, books and companies are springing up to help consumers navigate test-taking and interpretation.

Finding an expert specifically trained at the graduate level in genetics a genetic counselor, PhD geneticist, or MD with genetics/genomics training is challenging because their priorities are in clinical testing, not the entertainment/education space that the consumer companies so ceaselessly promote. Other scientists may be helpful molecular biologists, biochemists but genetics as a discipline transcends DNA, including developmental, transmission, and population and evolutionary genetics too. Ancestry testing in particular melds these levels of genetics.

Assuming a sit-down with an expert to intrepret consumer DNA data isnt happening easily, here are some places to turn.

A longstanding helpful website is Genetics Home Reference, from the NIH.

A newer resource is this report from ConsumersAdvocate.org. Their researchers recently sent DNA anonymously to 9 leading consumer DNA testing companies, interpreted the data, and then wrote a detailed, clear analysis that compares the services, privacy/security measures, online resources, and cost of tests.

Consumer DNA testing is a fast-growing industry with over 26 million users worldwide. That number is expected to grow to 100 million by 2021, Sam Klau, Community Outreach at the organization, told me.

An excellent new book is DNA Nation: How the Internet of Genes is Changing Your Life, by PhD molecular biologist Sergio Pistoi. And my human genetics textbook will be out in a new edition in September. Ive added a chapter called The Genetics of Identity, inspired by having my past rewritten recently thanks to ancestry testing.

The testing company websites, like that of 23andme, provide clear and well-written info on interpreting test results. But without any prior knowledge of genetics, misinterpretation and misplaced angst can arise.

Does the average person know the difference in significance between revealing a pattern of genome-wide single-base variations (SNPs) associated with elevated risk of a trait or illness, and detecting a well-studied mutation in a single gene?

The raw data dump from consumer DNA testing can be overwhelming, and to paraphrase Elizabeth Warren: Theres a company for that. A consumer can pay to avoid bushwhacking through dense SNP forests.

Strategene, for example, is a genetic reporting tool that uses 23andMe data to identify SNPs in a few dozen well-studied, health-related genes, and not every SNP under the sun. The $45 is a sound investment; it would take hours to sort through Google Scholar to DIY. But the client needs to know about the limited variant issue of checking only for common SNPs.

(I was briefly fooled into confusing the company with 1980s biotech giant Stratagene, but its off by one letter and one capitalization. The only person named on the company website is a naturopath referred to many times as Dr., which wouldnt necessarily denote a genetics expert.)

Im curious to see how soon the medical profession catches up. Right now, genetic counselors in the US number only about 5,000. But professional organizations are stepping in. The American College of Medical Genetics and Genomics, for example, offers online continuing medical education, ACMG Genetics 101 for Healthcare Providers.

But doctors Ive encountered recently still go deer-in-the-headlights when I ask a genetics question, just to be obnoxious. And so a company like ActXmakes sense in helping medical professionals keep pace with the growing tide of patients coming in waving consumer DNA test results. The company helps physicians and patients apply 23andMe raw data to select drugs, order clinical tests to help diagnose specific conditions, and to confirm carrier status for single-gene diseases.

When I started my career as a Drosophila geneticist, mutating flies to grow legs out of their heads, I never imagined at-home DNA testing. When I started my career as a science writer and textbook author, I still couldnt have predicted at-home DNA testing. Now that its here, Im thrilled that DNA science has become so much more tangible and practical. Yet we must use the information in our strings of A, C, T, and G wisely.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

See the original post:
Does the 'genetics revolution' unsettle you? Here is a guide, and reasons to be hopeful - Genetic Literacy Project

Posted in Genetics | Comments Off on Does the ‘genetics revolution’ unsettle you? Here is a guide, and reasons to be hopeful – Genetic Literacy Project

DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market – Benzinga

Posted: December 12, 2019 at 12:45 pm

OG DNA Genetics recently disclosed a licensing agreement in conjunction with Green Peak Innovations, a medical cannabis producer and distributor in the Michigan market.

This arrangement will concede Green Peak Innovations consent to the DNA brand and access to their genetics portfolio for use at the companys cannabis cultivation and processing plant in Harvest Park, Michigan. Additionally to growing DNA genetics, Green Peak has entered the retail sector, with several locations around the state.

The recent permit of adult-use cannabis police in Michigan will enable Green Peak to supply recreational and medical users high-quality strains.

Want to hear exclusive updates on the adult-use licensing process? Check out the next meetup with MRA Executive Director, Andrew Brisbo on Dec. 18 at the Benzinga Headquarters! Get your tickets here before they sell out!

"By partnering with Green Peak Innovations, we position ourselves to expand into the rapidly developing Michigan cannabis market alongside a proven and trusted cannabis producer and distributor," said Charles Phillips, CEO of DNA Genetics.

Jeff Radway, CEO of Green Peak Innovations said, "We appreciate what DNA has accomplished for the cannabis industry and are excited to partner with them. We believe that by incorporating DNAs library of best-in-class cultivars and award-winning genetics into our facility, we can further enhance our ability to deliver the highest-quality products to Michigan and eventually the entire United States."

2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View original post here:
DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market - Benzinga

Posted in Genetics | Comments Off on DNA Genetics Announces Agreement With Green Peak To Make The Most Of Michigan Adult-Use Cannabis Market – Benzinga

10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. – BuzzFeed News

Posted: December 12, 2019 at 12:45 pm

Ariel Davis for BuzzFeed NewsShare on Facebook Share on Facebook Share on Pinterest Share on Pinterest Pinterest Pinterest

Genetics just got personal. So boasted the website of 23andMe in 2008, just after launching its DNA testing service.

As we entered this decade, a small cohort of companies 23andMe, its Silicon Valley neighbor Navigenics, and Icelandic competitor deCODE Genetics were selling a future of personalized medicine: Patients would hold the keys to longer and healthier lives by understanding the risks written into their DNA and working with their doctors to reduce them.

We all carry this information, and if we bring it together and democratize it, we could really change health care, 23andMe cofounder Anne Wojcicki told Time magazine when it dubbed the companys DNA test 2008s invention of the year, beating out Elon Musks Tesla Roadster.

But in reality, the 2010s would be when genetics got social. As the decade comes to a close, few of us have discussed our genes with our doctors, but millions of us have uploaded our DNA profiles to online databases to fill in the details of our family trees, explore our ethnic roots, and find people who share overlapping sequences of DNA.

Advertisement

Its become like Facebook for genes, driven by the same fundamental human desire to connect. And, as with Mark Zuckerbergs social media behemoth, this is the decade we reckoned with what it really means to hand over some of our most personal data in the process.

A 23andMe saliva collection kit for DNA testing.

It all panned out differently from the way I imagined in 2009, when I paid $985 to deCODE and $399 to 23andMe to put my DNA into the service of science journalism. (I spared my then-employer, New Scientist magazine, the $2,500 charge for the boutique service offered by Navigenics.)

I was intrigued by the potential of DNA testing for personalized medicine, but from the beginning, I was also concerned about privacy. I imagined a future in which people could steal our medical secrets by testing the DNA we leave lying around on discarded tissues and coffee cups. In 2009, a colleague and I showed that all it took to hack my genome in this way was a credit card, a private email account, a mailing address, and DNA testing companies willing to do business without asking questions.

Advertisement

Much of the rest of what I wrote about DNA testing back then reflected pushback from leading geneticists who argued that the companies visions of personalized medicine werent ready for primetime.

As I explored the reports offered by 23andMe and deCODE, I couldnt help but agree especially when deCODE wrongly concluded that I carry two copies of a variant of a gene that would give me a 40% lifetime chance of developing Alzheimers. (Luckily, it wasnt cause for panic. Id pored over my DNA in enough detail by then to know that I carry only one copy, giving me a still-elevated but much less scary lifetime risk of about 13%.)

Despite such glitches, it still seemed that medicine was where the payoffs of mainstream genetic testing were going to be. As costs to sequence the entire genome plummeted, I expected gene-testing firms to switch from using gene chips that scan hundreds of thousands of genetic markers to new sequencing technology that would allow them to record all 3 billion letters of our DNA.

So in 2012, eager to provide our readers with a preview of what was to come, New Scientist paid $999 for me to have my exome sequenced in a pilot project offered by 23andMe. This is the 1.5% of the genome that is read to make proteins and is where the variants that affect our health are most likely to lurk.

Experts at the Medical College of Wisconsin in Milwaukee analyzed my exome. While they werent at that point able to tell me much of medical significance that I didnt already know, the article I wrote from the experience in 2013 predicted a future in which doctors would routinely scour their patients genomes for potential health problems and prescribe drugs that have been specifically designed to correct the biochemical pathways concerned.

Advertisement

Im glad I included an important caveat: This may take several decades.

By then, the revolution promised by 23andMe and its competitors was faltering. Navigenics and deCODE had both been acquired by bigger companies and stopped selling DNA tests directly to the public.

23andMe, backed by the deep pockets of Google and other Silicon Valley investors, had enough cash to continue. But it fell foul of the FDA, which had decided that the company was selling medical devices that needed official approval to be put on the market. In a 2013 warning letter, the FDA said that 23andMe had failed to provide adequate evidence that its tests produced accurate results. By the end of 2013, 23andMe had stopped offering assessments of health risks to new customers.

Since then, the company has slowly clawed its way back into the business of health. In 2015, it was given FDA approval to tell customers whether they were carriers for a number of inherited diseases; in 2017, it started providing new customers with assessments of health risks once more.

I recently updated my 23andMe account, getting tested on the latest version of its chip. My results included reports on my genetic risk of experiencing 13 medical conditions. Back in 2013, there were more than 100 such reports, plus assessments of my likely responses to a couple dozen drugs.

In the lab, discovery has continued at a pace, but relatively few findings have found their way into the clinic.

Advertisement

If youve recently been pregnant, you were probably offered blood tests to tell whether your fetus had a serious genetic abnormality. And if youve been diagnosed with cancer, a biopsy may have been sequenced to look for mutations that make some drugs a good bet and other ones a bust. Neither would have been common a decade ago.

But the wider health care revolution envisaged by Wojcicki remains far off.

A few weeks ago, I saw my doctor to discuss my moderately high blood cholesterol and had a conversation that Id once predicted would be common by now. I had signed up for a project called MyGeneRank, which took my 23andMe data and calculated my genetic risk of experiencing coronary artery disease based on 57 genetic markers, identified in a 2015 study involving more than 180,000 people.

My genetic risk turns out to be fairly low. After I pulled out my phone and showed my doctor the app detailing my results, we decided to hold off on taking a statin for now, while I make an effort to improve my diet and exercise more. But it was clear from her reaction that patients dont usually show up wanting to talk about their DNA.

We have all these naysayers and an immense body of research that is not being used to help patients, said Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, which runs the MyGeneRank project.

Advertisement

Joseph James DeAngelo, the suspected "Golden State Killer," appears in court for his arraignment in Sacramento, April 27, 2018.

23andMes collision with the FDA wound up being a turning point in ways I didnt anticipate at the time. From the start, the company included an assessment of customers ancestries as part of the package. But after the FDA cracked down, it pivoted to make ancestry and finding genetic relatives its main focus. Offering the test at just $99, 23andMe went on a marketing blitz to expand its customer base competing with a new rival.

Ancestry.com launched its genome-scanning service in May 2012 and has since gone head-to-head with 23andMe through dueling TV ads and Black Friday discount deals.

DNA tests became an affordable stocking filler, as millions of customers were sold a journey of self-discovery and human connection. We were introduced to new genetic relatives. And we were told that the results might make us want to trade in our lederhosen for a kilt or connect us to distant African ancestors.

Today, Ancestrys database contains some 15 million DNA profiles; 23andMes more than 10 million. Family Tree DNA and MyHeritage, the two other main players, have about 3.5 million DNA profiles between them. And for the most dedicated family history enthusiasts, there is GEDmatch, where customers can upload DNA profiles from any of the main testing companies and look for potential relatives. It contains about 1.2 million DNA profiles.

Advertisement

So far, so much fun. But DNA testing can reveal uncomfortable truths, too. Families have been torn apart by the discovery that the man they call Dad is not the biological father of his children. Home DNA tests can also be used to show that a relative is a rapist or a killer.

That possibility burst into the public consciousness in April 2018, with the arrest of Joseph James DeAngelo, alleged to be the Golden State Killer responsible for at least 13 killings and more than 50 rapes in the 1970s and 1980s. DeAngelo was finally tracked down after DNA left at the scene of a 1980 double murder was matched to people in GEDmatch who were the killer's third or fourth cousins. Through months of painstaking work, investigators working with the genealogist Barbara Rae-Venter built family trees that converged on DeAngelo.

Genealogists had long realized that databases like GEDmatch could be used in this way, but had been wary of working with law enforcement fearing that DNA test customers would object to the idea of cops searching their DNA profiles and rummaging around in their family trees.

But the Golden State Killers crimes were so heinous that the anticipated backlash initially failed to materialize. Indeed, a May 2018 survey of more than 1,500 US adults found that 80% backed police using public genealogy databases to solve violent crimes.

Advertisement

I was very surprised with the Golden State Killer case how positive the reaction was across the board, CeCe Moore, a genealogist known for her appearances on TV, told BuzzFeed News a couple of months after DeAngelos arrest.

The new science of forensic genetic genealogy quickly became a burgeoning business, as a company in Virginia called Parabon NanoLabs, which already had access to more than 100 crime scene samples through its efforts to produce facial reconstructions from DNA, teamed up with Moore to work cold cases through genealogy.

Before long, Parabon and Moore were identifying suspected killers and rapists at the rate of about one a week. Intrigued, my editor and I decided to see how easy it would be to identify 10 BuzzFeed employees from their DNA profiles, mimicking Parabons methods. In the end, I found four through matches to their relatives DNA profiles and another two thanks to their distinctive ancestry. It was clear that genetic genealogy was already a powerful investigative tool and would only get more so as DNA databases continued to grow.

A backlash did come, however, after two developments revealed by BuzzFeed News in 2019. In January, Family Tree DNA disclosed that it had allowed the FBI to search its database for partial matches to crime-scene samples since the previous fall without telling its customers. I feel they have violated my trust, Leah Larkin, a genetic genealogist based in Livermore, California, told BuzzFeed News at the time.

Then, in May, BuzzFeed News reported that police in Centerville, Utah, had convinced Curtis Rogers, a retired Florida businessperson who cofounded GEDmatch, to breach the sites own terms and conditions, which were supposed to restrict law enforcement use to investigations of homicides or sexual assaults. That allowed Parabon to use matches in the database to identify the perpetrator of a violent assault.

Advertisement

Larkin and other genealogists condemned the move, calling it the start of a slippery slope that would see the method being used to investigate more trivial crimes.

As barbs flew between genealogists working with law enforcement and those who advocate for genetic privacy, GEDmatch responded with new terms of service that extended the definition of violent crime, but also required users to explicitly opt in for their DNA profiles to be included in law enforcement searches.

Overnight, GEDmatch became useless for criminal investigations. Since then, the number of users opting in for matching to crime-scene samples has slowly increased, and now stands at more than 200,000. But progress in cracking criminal cases has remained slow.

Now that cops have seen the power of forensic genetic genealogy, however, they dont want to let it go. In November, the New York Times revealed that a detective in Florida had obtained a warrant to search the entirety of GEDmatch, regardless of opt-ins. It seems only a matter of time before someone tries to serve a warrant to search the huge databases of 23andMe or Ancestry, which dont give cops access sparking legal battles that could go all the way to the Supreme Court.

Genetic privacy, barely mentioned as millions of us signed up to connect with family across the world and dig into our ancestral roots, is suddenly front and center.

This week, Rogers and the other cofounder of GEDmatch, John Olson, removed themselves from the heat when they sold GEDmatch to Verogen, a company in San Diego that makes equipment to sequence crime-scene DNA. Verogen CEO Brett Williams told BuzzFeed News that he sees a business opportunity in charging police for access to the database but promised to respect users privacy. Were not going to force people to opt in, he said.

Advertisement

But it isnt just whether cops can run searches against your DNA. 23andMe may not share your information with law enforcement, but customers are asked when they signed up whether if they are OK with their de-identified DNA being used for genetic research.

It might not be obvious when you fill in the consent form, but this lies at the heart of 23andMes business model. The reason the company pushed so hard to expand its database of DNA profiles is to use this data in research to develop new drugs, either by itself or by striking deals with pharmaceutical companies.

Ancestry has also asked its users to consent to participate in research, teaming up with partners that have included Calico, a Google spinoff researching ways to extend human lifespan.

You might be comfortable with all of this. You might not. You should definitely think about it because when the information is your own DNA, there really is no such thing as de-identified data.

That DNA profile is inextricably tied to your identity. It might be stripped of your name and decoupled from the credit card you used to pay for the test. But as 23andMe warns in its privacy policy: In the event of a data breach it is possible that your data could be associated with your identity, which could be used against your interests.

Advertisement

And because you share a large part of your genome with close relatives, when you put your DNA profile into a companys database, you arent only making a decision for yourself: Their privacy is on the line, too.

Whether its due to concerns about privacy, a saturated market, or just that the novelty has worn off, sales of DNA ancestry tests are slowing. Ancestry has responded by offering a new product focused on health risks. Unlike 23andMe, it requires that tests are ordered through PWNHealth, a national network of doctors and genetic counselors.

Will this be the development that takes us back to the future I once imagined? Maybe so, but if the roller coaster of the past decade has taught me anything, its to be wary about making any predictions about our genetic future.

Peter Aldhous is a Science Reporter for BuzzFeed News and is based in San Francisco.

Contact Peter Aldhous at peter.aldhous@buzzfeed.com.

Got a confidential tip? Submit it here.

Read more:
10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. - BuzzFeed News

Posted in Genetics | Comments Off on 10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. – BuzzFeed News

Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk – Clinical OMICs News

Posted: December 12, 2019 at 12:45 pm

A genetic variant found in about 3% of people of African ancestry is a more significant cause of heart failure than previously believed, according to a multi-institution study led by researchers at Penn Medicine. The researchers also found that this type of heart failure is underdiagnosed. According to their study, 44% of TTR V122Ivariant carriers older than age 50 had heart failure, but only 11% of these individuals had been diagnosed with hATTR-CM. The average time to diagnosis was three years, indicating both high rates of underdiagnoses and prolonged time to appropriate diagnosis

This study suggests that workup for amyloid cardiomyopathy and genetic testing of TTR should be considered, when appropriate, to identify patients at risk for the disease and intervene before they develop more severe symptoms or heart failure, said the studys lead author Scott Damrauer, M.D., an assistant professor of Surgery at Penn Medicine and a vascular surgeon at the Corporal Michael J. Crescenz VA Medical Center. (Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania and the University of Pennsylvania Health System.)

In this study, researchers from Penn Medicine and the Icahn School of Medicine at Mount Sinai used a genome-first approach, performing DNA sequencing of 9,694 individuals of African and Latino ancestry enrolled in either the Penn Medicine BioBank (PMBB) or the Icahn School of Medicine at Mount Sinai BioMe biobank (BioMe). Researchers identified TTR V122I carriers and then examined longitudinal electronic health record-linked genetic data to determine which of the carriers had evidence of heart failure.

The findings, which were published today in JAMA, are particularly important given the US Food and Drug Administrations (FDA) approval of the first therapy (tafamidis) for ATTR-CM in May 2019. Prior to tafamidiss approval, treatment was largely limited to supportive care for heart failure symptoms and, in rare cases, heart transplant.

Our findings suggest that hATTR-CM is a more common cause of heart failure than its perceived to be, and that physicians are not sufficiently considering the diagnosis in certain patients who present with heart failure, said the studys corresponding author Daniel J. Rader, M.D., chair of the Department of Genetics at Penn Medicine. With the recent advances in treatment, its critical to identify patients at risk for the disease and, when appropriate, perform the necessary testing to produce an earlier diagnosis and make the effective therapy available.

hATTR-CM, also known as cardiac amyloidosis, typically manifests in older patients and is caused by the buildup of abnormal deposits of a specific transthyretin protein known as amyloid in the walls of the heart. The heart walls become stiff, resulting in the inability of the left ventricle to properly relax and adequately pump blood out of the heart. However, this type of heart failurewhich presents similar to hypertensive heart disease is common, and the diagnosis of hATTR-CM is often not considered.

Tafamidis meglumine is a non-NSAID benzoxazole derivative that binds to TTR with high affinity and selectivity. TTR acts by transporting the retinol-binding protein-vitamin A complex. It is also a minor transporter of thyroxine in blood. Its tetrameric structure can become amyloidogenic by undergoing rate-limiting dissociation and monomer misfolding.

See the original post here:
Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk - Clinical OMICs News

Posted in Genetics | Comments Off on Penn Team Finds Genetic Variant Largely Found in Patients of African Descent that Increases Heart Failure Risk – Clinical OMICs News

Page 1,232«..1020..1,2311,2321,2331,234..1,2401,250..»